Wikidata

(Q59236731)

English

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

article

In more languages
default for all languages
No label defined

No description defined

Statements

title
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity (English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
17761829
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17761829%20AND%20SRC:MED&resulttype=core&format=json
retrieved
4 January 2020
author name string

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q59236731&oldid=1901932469"